WO2021149776A1 - 抗腫瘍活性を有するアリールアミド誘導体 - Google Patents

抗腫瘍活性を有するアリールアミド誘導体 Download PDF

Info

Publication number
WO2021149776A1
WO2021149776A1 PCT/JP2021/002088 JP2021002088W WO2021149776A1 WO 2021149776 A1 WO2021149776 A1 WO 2021149776A1 JP 2021002088 W JP2021002088 W JP 2021002088W WO 2021149776 A1 WO2021149776 A1 WO 2021149776A1
Authority
WO
WIPO (PCT)
Prior art keywords
fluoro
methyl
compound
group
iodoanilino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2021/002088
Other languages
English (en)
French (fr)
Japanese (ja)
Inventor
義明 一色
渡辺　史郎
正樹 富澤
樹人 羽田
服部　一夫
川崎　健一
郁美 兵藤
紀裕 青木
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to DK21744061.9T priority Critical patent/DK4094804T3/da
Priority to CR20220390A priority patent/CR20220390A/es
Priority to PE2022001439A priority patent/PE20230239A1/es
Priority to EP21744061.9A priority patent/EP4094804B1/en
Priority to SI202130384T priority patent/SI4094804T1/sl
Priority to RS20260093A priority patent/RS67669B1/sr
Priority to ES21744061T priority patent/ES3060503T3/es
Priority to LTEPPCT/JP2021/002088T priority patent/LT4094804T/lt
Priority to HRP20260094TT priority patent/HRP20260094T1/hr
Priority to CN202180008024.XA priority patent/CN114929669B/zh
Priority to EP25226973.3A priority patent/EP4725941A1/en
Priority to BR112022009518A priority patent/BR112022009518A2/pt
Priority to IL294916A priority patent/IL294916B1/en
Priority to KR1020227041183A priority patent/KR102904379B1/ko
Priority to MX2022008722A priority patent/MX2022008722A/es
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Priority to FIEP21744061.9T priority patent/FI4094804T3/fi
Priority to AU2021211553A priority patent/AU2021211553A1/en
Priority to JP2021536299A priority patent/JP6971432B1/ja
Priority to MA58427A priority patent/MA58427B1/fr
Priority to KR1020227002880A priority patent/KR102473971B1/ko
Priority to CA3168788A priority patent/CA3168788A1/en
Priority to PL21744061.9T priority patent/PL4094804T3/pl
Publication of WO2021149776A1 publication Critical patent/WO2021149776A1/ja
Priority to JP2021178868A priority patent/JP7693513B2/ja
Priority to US17/869,226 priority patent/US11964950B2/en
Anticipated expiration legal-status Critical
Priority to CONC2022/0011429A priority patent/CO2022011429A2/es
Priority to US18/608,369 priority patent/US20240246922A1/en
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/02—1,2-Oxazines; Hydrogenated 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/43—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C211/54—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to two or three six-membered aromatic rings
    • C07C211/55—Diphenylamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C307/00—Amides of sulfuric acids, i.e. compounds having singly-bound oxygen atoms of sulfate groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C307/02—Monoamides of sulfuric acids or esters thereof, e.g. sulfamic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C307/00—Amides of sulfuric acids, i.e. compounds having singly-bound oxygen atoms of sulfate groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C307/04—Diamides of sulfuric acids
    • C07C307/10—Diamides of sulfuric acids having nitrogen atoms of the sulfamide groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/14—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/23—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atoms of the sulfonamide groups bound to acyclic carbon atoms
    • C07C311/24—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atoms of the sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/23—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atoms of the sulfonamide groups bound to acyclic carbon atoms
    • C07C311/25—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atoms of the sulfonamide groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/48—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups having nitrogen atoms of sulfonamide groups further bound to another hetero atom
    • C07C311/49—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups having nitrogen atoms of sulfonamide groups further bound to another hetero atom to nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C07C317/48—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C317/50—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C333/00—Derivatives of thiocarbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C333/14—Dithiocarbamic acids; Derivatives thereof
    • C07C333/18—Esters of dithiocarbamic acids
    • C07C333/20—Esters of dithiocarbamic acids having nitrogen atoms of dithiocarbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/24—Halogenated derivatives
    • C07C39/26—Halogenated derivatives monocyclic monohydroxylic containing halogen bound to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/76—Nitrogen atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D305/04—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D305/06—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D305/04—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D305/08—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/14—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/72—Benzo[c]thiophenes; Hydrogenated benzo[c]thiophenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/027—Organoboranes and organoborohydrides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring

Definitions

  • the present disclosure is effective for arylamide derivatives having RAF / MEK complex stabilizing activity and / or MEK inhibitory activity and useful for the treatment or prevention of cell proliferation diseases, particularly cancer, and such arylamide derivatives.
  • the present invention relates to a RAF / MEK complex stabilizer or MEK inhibitor contained as an ingredient.
  • MEK mitogen-activated protein kinase kinase
  • MAPK MAPK signaling pathway
  • PD0325901, CH4987655, trametinib, cobimetinib, selmethinib and the like have been reported as MEK inhibitors (see Patent Document 1 and Non-Patent Document 2), and cancers having RAF mutations alone or in combination with RAF inhibitors. For example, it has been reported to have a clinical effect on malignant melanoma having a BRAF mutation (see Non-Patent Documents 3 and 4).
  • CH51267666 (see Patent Document 2 and Non-Patent Documents 7 and 8), which is known not only as a MEK inhibitor but also as a stabilizer for the RAF / MEK complex, is clinically used for non-small cell lung cancer having a RAS mutation. It has been reported that the above effects are exhibited (see Non-Patent Document 9). It has also been reported that CH5126766 stabilizes the RAF / MEK complex and suppresses the enhancement of MEK phosphorylation (feedback activation of the MAPK signal pathway) (see Non-Patent Document 10) (Non-Patent Document 7). And 8). This feedback activation is also considered to be one of the reasons why the clinical effect of MEK inhibitors on cancers having RAS mutations is not always sufficient (see Non-Patent Document 10).
  • the present disclosure is a novel compound having RAF / MEK complex stabilizing activity and / or MEK inhibitory activity and useful for the treatment or prevention of cell proliferation diseases, particularly cancer, or cell proliferation diseases, in particular. It is an object of the present invention to provide a novel RAF / MEK complex stabilizer or MEK inhibitor useful for the treatment or prevention of cancer.
  • CH4987655 which is a known MEK inhibitor
  • CH51267666 which is a known RAF / MEK complex stabilizer
  • CH4987655 shows comparable MEK inhibitory activity in non-cellular lines but slower deviation from MEK when compared to another MEK inhibitor, PD0325901. Then, in the cynomolgus monkey peripheral blood showed strong MEK inhibitory activity than PD0325901 (low IC 50 of), to realize a MEK inhibitor longer lasting. They are believed to be due to a characteristic substituent containing a 3-oxo- [1,2] oxadinane ring structure located at the 5'position of the benzamide skeleton of CH4987655 (Bioorg. Med. Chem. Lett.2011, vol.21, no.6, p.1795-1801).
  • CH5126766 forms a complex with MEK in a characteristic structure. That is, when CH51267666 binds to MEK, the MEK activation segment moves, and accordingly, Asn221 and Ser222 of MEK are placed in spatially different locations than when PD0325089 (enantiomer of PD0325901) binds.
  • the sulfamide group of CH5126766 has a hydrogen bond with Asn221 of MEK directly and with Ser222 via water. Since Ser222 is one of the two amino acids phosphorylated by RAF, the RAF / MEK complex stabilizing action and MEK phosphorylation enhancing (feedback activation of MAPK signal pathway) inhibitory action of CH5126766 are such. It is believed to be due to the complex structure (see Cancer Cell. 2014, vol. 25, no. 5, p. 697-710 (Non-Patent Document 8)).
  • CH4987655 when bound to MEK, results in a spatial arrangement of Asn221 and Ser222 similar to CH51267666. It is also similar to CH5126766 in that it interacts with Asn221. Although CH4987655 is weak, it has an inhibitory effect on the enhancement of MEK phosphorylation, which is considered to be due to such a complex structure (Cancer Cell.2014, vol.25, no.5, 5). See p. 697-710 (Non-Patent Document 8)).
  • CH4987655 differs from CH5126766 in that it is distant from Ser222 and does not interact with it, and its interaction with Asn221 is weak via the 3-oxo- [1,2] oxadinane ring structure. On the other hand, CH51267666 does not interact with Lys97, unlike MEK inhibitors such as CH4987655 and PD0325901.
  • Hypothesis 1 If a chemical structure capable of hydrogen-bonding with Lys97 is introduced into CH51267666, the RAF / MEK complex stabilizing activity and MEK phosphorylation enhancement (feedback activation of MAPK signal pathway) inhibitory activity of CH51267666 are maintained. At the same time, MEK inhibitory activity equivalent to that of CH4987655 can be obtained.
  • Hypothesis 2 If a chemical structure capable of forming a strong hydrogen bond with Asn221 and Ser222 is introduced into CH4987655, the RAF / MEK complex stabilizing activity equivalent to that of CH5126766 and MEK phosphorus are maintained while maintaining the MEK inhibitory activity of CH4987655. It is possible to obtain an activity of suppressing the enhancement of oxidation (feedback activation of the MAPK signal pathway).
  • HCT-116 and Colo-205 were obtained from ATCC). The results are shown in Table 1 below.
  • HCT-116 and Color-205 are human cancer cells having a RAS mutation and a BRAF mutation, respectively.
  • compound AA-2 did not acquire the expected profile.
  • compound AA-1 showed remarkable MEK1 inhibitory activity, BRAF inhibitory activity, HCT-116 growth inhibitory activity and Colo-205 proliferation inhibitory activity.
  • the present inventor has a specific arylamide derivative having RAF / MEK complex stabilizing activity and / or MEK inhibitory activity, and cell proliferation diseases, particularly It has been found to be useful in the treatment or prevention of cancer.
  • (A1) A compound represented by the following general formula (1) or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of the compound or salt.
  • Ring A has the following general formulas (2), (3), (4) or (5) (where, the bonds with *, ** and *** are -NH-, -CONH- and, respectively. It is a group represented by -CH 2-bonded to-).
  • R 2 is a hydrogen atom, a halogen atom or a C1 ⁇ 6 alkyl group
  • R 8 and R 8 is substituted with a hydrogen atom and a C1 to 6 alkyl group (the C1 to 6 alkyl group is substituted with a halogen atom, a hydroxy group, a C1 to 6 alkoxy group, a C3 to 6 cycloalkyl group or a C3 to 6 heterocycloalkyl group.
  • R 3 is a hydrogen atom, a C1 to 6 alkyl group (the C1 to 6 alkyl group may be substituted with a halogen atom, a hydroxy group or a C1 to 6 alkoxy group), and a C3 to 6 cycloalkyl group (the C3).
  • the ⁇ 6 cycloalkyl groups may be substituted with halogen atoms or C1-6 alkyl groups) or C1-6 alkoxy groups (the C1-6 alkoxy groups are substituted with halogen atoms, hydroxy groups or C1-6 alkoxy groups). It may have been done.)
  • R 5 is a halogen atom or a C1-6 alkyl group.
  • R 6 is a hydrogen atom, a halogen atom or a C1 to 6 alkyl group
  • R 4 is a hydrogen atom, a halogen atom, a C1 to 6 alkyl group, a C2 to 7 alkenyl group, a C2 to 7 alkynyl group and a C3 to 6 cycloalkyl group.
  • R 6 and R 4 forms a together with the carbon atom bonded unsaturated heterocyclic 5-membered ring
  • R 7 is a hydrogen atom or a C1-6 alkyl group
  • R 9 is a hydrogen atom, a halogen atom or a C1-6 alkyl group.
  • Ring A is a group represented by the general formula (2) or (4).
  • R 8 is a hydrogen atom, a C1 to 6 alkyl group (the C1 to 6 alkyl group may be substituted with a halogen atom, a hydroxy group or a C1 to 6 alkoxy group) or a monocyclic C3 to 6 cycloalkyl. It is a group (the C3 to 6 cycloalkyl group may be substituted with a C1 to 6 alkyl group).
  • R 3 is a hydrogen atom, a C1 to 6 alkyl group, a C3 to 6 cycloalkyl group, or a C1 to 6 alkoxy group (the C1 to 6 alkoxy group may be substituted with a hydroxy group).
  • R 6 is a hydrogen atom, a halogen atom or a C1-6 alkyl group
  • R 4 is a halogen atom or a cyclopropyl group.
  • R 7 is a hydrogen atom or a methyl group, The compound, salt or solvate according to (A1).
  • the compound represented by the general formula (1) is a compound represented by the following general formula (6), the compound, salt or solvate according to (A1).
  • R 2 is a hydrogen atom, a halogen atom or a C1 ⁇ 6 alkyl group
  • R 8 and R 8 is a hydrogen atom, a C1 to 6 alkyl group (the C1 to 6 alkyl group may be substituted with a halogen atom, a hydroxy group or a C1 to 6 alkoxy group) or a monocyclic C3 to 6 cycloalkyl. It is a group (the C3 to 6 cycloalkyl group may be substituted with a C1 to 6 alkyl group).
  • R 3 is a hydrogen atom, a C1 to 6 alkyl group, a C3 to 6 cycloalkyl group, or a C1 to 6 alkoxy group (the C1 to 6 alkoxy group may be substituted with a hydroxy group).
  • R 5 is a halogen atom or a C1-6 alkyl group.
  • R 6 is a hydrogen atom, a halogen atom or a C1-6 alkyl group, and R 4 is a halogen atom or a cyclopropyl group.
  • R 2 is a hydrogen atom or a halogen atom
  • R 8 is a C1 to 6 alkyl group (the C1 to 6 alkyl group may be substituted with a halogen atom or a C1 to 6 alkoxy group) or a monocyclic C3 to 6 cycloalkyl group (the C3 to 6).
  • the cycloalkyl group may be substituted with a C1-6 alkyl group).
  • R 3 is a hydrogen atom, a C1 to 6 alkyl group, a C3 to 6 cycloalkyl group, or a C1 to 6 alkoxy group (the C1 to 6 alkoxy group may be substituted with a hydroxy group).
  • R 5 is a halogen atom
  • R 6 is a hydrogen atom and R 4 is a halogen atom or a cyclopropyl group.
  • R 2 is a hydrogen atom or a fluorine atom
  • R 8 is a C1 to 4 alkyl group (the C1 to 4 alkyl group may be substituted with a fluorine atom or a C1 to 4 alkoxy group) or a cyclopropyl group (the cyclopropyl group is a C1 to 4 alkyl group). It may have been replaced.
  • R 3 is a hydrogen atom, a C1 to 4 alkyl group, a cyclopropyl group or a C1 to 4 alkoxy group (the C1 to 4 alkoxy group may be substituted with a hydroxy group).
  • R 5 is a fluorine atom
  • R 6 is a hydrogen atom
  • R 4 is an iodine atom or cyclopropyl group.
  • R 2 is a fluorine atom
  • R 3 is a hydrogen atom or cyclopropyl group
  • R 5 is a fluorine atom
  • R 6 is a hydrogen atom
  • R 4 is an iodine atom or cyclopropyl group.
  • the present disclosure also provides the agents described in (A7)-(A10) below.
  • the compound, salt or solvate described in (A7) below includes the compound, salt or solvate described in (A1) to (A6).
  • (A7) A stabilizer for a RAF / MEK complex containing a compound represented by the following general formula (11) or a pharmaceutically acceptable salt thereof or a pharmaceutically acceptable solvate of the compound or salt as an active ingredient.
  • Ring A has the following general formulas (2), (3), (4) or (5) (where, the bonds with *, ** and *** are -NH-, -CONH- and, respectively. -X 7 -.
  • R 2 is a hydrogen atom, a halogen atom or a C1 ⁇ 6 alkyl group
  • X 7 is-(CH 2 ) m -or -O- and m is 1, 2 or 3.
  • R 3 is a hydrogen atom, a C1 to 6 alkyl group (the C1 to 6 alkyl group may be substituted with a halogen atom, a hydroxy group or a C1 to 6 alkoxy group), and a C3 to 6 cycloalkyl group (the C3).
  • the ⁇ 6 cycloalkyl groups may be substituted with halogen atoms or C1-6 alkyl groups) or C1-6 alkoxy groups (the C1-6 alkoxy groups are substituted with halogen atoms, hydroxy groups or C1-6 alkoxy groups).
  • R 5 is a hydrogen atom, a halogen atom or a C1-6 alkyl group.
  • R 6 is a hydrogen atom, a halogen atom or a C1 to 6 alkyl group, and R 4 is a hydrogen atom, a halogen atom, a C1 to 6 alkyl group, a C2 to 7 alkenyl group, a C2 to 7 alkynyl group and a C3 to 6 cycloalkyl group.
  • R 6 and R 4 forms a together with the carbon atom bonded unsaturated heterocyclic 5-membered ring
  • R 7 is a hydrogen atom or a C1-6 alkyl group
  • R 9 is a hydrogen atom, a halogen atom or a C1-6 alkyl group.
  • Ring A is a group represented by the general formula (2) or (4).
  • X 7 is -CH 2-
  • R 8 is a hydrogen atom, a C1 to 6 alkyl group (the C1 to 6 alkyl group may be substituted with a halogen atom, a hydroxy group or a C1 to 6 alkoxy group) or a monocyclic C3 to 6 cycloalkyl. It is a group (the C3 to 6 cycloalkyl group may be substituted with a C1 to 6 alkyl group).
  • R 3 is a hydrogen atom, a C1 to 6 alkyl group, a C3 to 6 cycloalkyl group, or a C1 to 6 alkoxy group (the C1 to 6 alkoxy group may be substituted with a hydroxy group).
  • R 5 is a halogen atom or a C1-6 alkyl group.
  • R 6 is a hydrogen atom, a halogen atom or a C1-6 alkyl group, and R 4 is a halogen atom or a cyclopropyl group.
  • R 7 is a hydrogen atom or a methyl group, The stabilizer for the RAF / MEK complex according to (A7).
  • R 2 is a hydrogen atom, a halogen atom or a C1 ⁇ 6 alkyl group
  • R 8 and R 8 is a hydrogen atom, a C1 to 6 alkyl group (the C1 to 6 alkyl group may be substituted with a halogen atom, a hydroxy group or a C1 to 6 alkoxy group) or a monocyclic C3 to 6 cycloalkyl. It is a group (the C3 to 6 cycloalkyl group may be substituted with a C1 to 6 alkyl group).
  • R 3 is a hydrogen atom, a C1 to 6 alkyl group, a C3 to 6 cycloalkyl group, or a C1 to 6 alkoxy group (the C1 to 6 alkoxy group may be substituted with a hydroxy group).
  • R 5 is a halogen atom or a C1-6 alkyl group.
  • R 6 is a hydrogen atom, a halogen atom or a C1-6 alkyl group, and R 4 is a halogen atom or a cyclopropyl group.
  • R 2 is a hydrogen atom or a halogen atom
  • R 8 is a C1 to 6 alkyl group (the C1 to 6 alkyl group may be substituted with a halogen atom or a C1 to 6 alkoxy group) or a monocyclic C3 to 6 cycloalkyl group (the C3 to 6).
  • the cycloalkyl group may be substituted with a C1-6 alkyl group).
  • R 3 is a hydrogen atom, a C1 to 6 alkyl group, a C3 to 6 cycloalkyl group, or a C1 to 6 alkoxy group (the C1 to 6 alkoxy group may be substituted with a hydroxy group).
  • R 5 is a halogen atom
  • R 6 is a hydrogen atom
  • R 4 is a halogen atom or a cyclopropyl group.
  • the present disclosure also provides the compounds, salts or solvates described in (A11)-(A15) below.
  • the compound, salt or solvate described in (A7) includes the compounds, salts or solvates described in (A11) to (A15) below.
  • (A11) N-Cyclopropyl-3,4-difluoro-2- (2-fluoro-4-iodoanilino) -5-[[3-fluoro-2- (methylsulfamoylamino) pyridin-4-yl] methyl] benzamide
  • Compound A-2 2- (2-Fluoro-4-iodoanilino) -5-[[3-fluoro-2- (methylsulfamoylamino) pyridin-4-yl] methyl] -1-methyl-6-oxopyridine-3-carboxamide
  • Compound J-1 2- (4-Cyclopropyl-2-fluoroanilino) -3,4-di
  • the compounds, salts or solvates according to (A1) to (A15) have high RAF / MEK complex stabilizing activity and have cell proliferation diseases, especially cancer (more specifically, for example, RAS mutations). It can be used as an active ingredient of a therapeutic or prophylactic agent for cancer). That is, the present disclosure also provides a pharmaceutical composition containing the compound, salt or solvate according to any one of (A1) to (A15) as an active ingredient. Further, a therapeutic or prophylactic agent for a cell proliferation disease, particularly cancer, containing the compound, salt or solvate according to any one of (A1) to (A15) as an active ingredient is provided.
  • the present disclosure also provides the compounds, salts or solvates described in (B1) to (B3) below and the agents described in (B4) below.
  • (B1) A compound represented by the following general formula (1) or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of the compound or salt.
  • Ring A is represented by the following general formula (2), (3) or (4) (wherein, *, respectively ** and a bond that is attached *** -NH -, - CONH- and -CH 2 - It is a group represented by) and is bonded to.
  • R 2 is a hydrogen atom, a halogen atom or a C1 ⁇ 4 alkyl group
  • R 8 and R 8 may be substituted with a C1-4 alkyl group (the C1-4 alkyl group may be substituted with a halogen atom, a hydroxy group, a C1-4 alkoxy group, a C3-6 cycloalkyl group or a C3-6 heterocycloalkyl group. )
  • C3 to 6 cycloalkyl groups the C3 to 6 cycloalkyl groups may be substituted with C1 to 4 alkyl groups).
  • R 3 is a hydrogen atom, a C3 to 6 cycloalkyl group or a C1 to 6 alkoxy group.
  • R 5 is a halogen atom
  • R 6 is a hydrogen atom and
  • R 4 is a halogen atom or a C3-6 cycloalkyl group.
  • R 7 is a C1-4 alkyl group
  • R 9 is a hydrogen atom.
  • (B4) A MEK inhibitor containing the compound, salt or solvate according to any one of (B1) to (B3) as an active ingredient.
  • the compounds, salts or solvates according to (B1) to (B3) have high MEK inhibitory activity and treat cell proliferation diseases, particularly cancers (more specifically, cancers having a RAF mutation, for example). Alternatively, it can be used as an active ingredient of a preventive agent. That is, the present disclosure also provides a pharmaceutical composition containing the compound, salt or solvate according to any one of (B1) to (B3) as an active ingredient. Further, a therapeutic or prophylactic agent for a cell proliferation disease, particularly cancer, containing the compound, salt or solvate according to any one of (B1) to (B3) as an active ingredient is provided.
  • Novel RAF / MEK complex stabilizers or MEK inhibitors useful for treatment or prevention are provided.
  • FIG. 1 shows a powder X-ray diffraction pattern of sample A-1a (FormI).
  • FIG. 2 shows a powder X-ray diffraction pattern of sample A-1b.
  • FIG. 3 shows a powder X-ray diffraction pattern of sample A-1c.
  • FIG. 4 shows MEK1 added to the surface of the sensor chip on which RAF1 is immobilized together with the test compound (ref-2, ref-3, ref-4, A-1, ref-1, ref-5 or B-1). It is a sensorgram which shows the time course of the binding amount of.
  • FIG. 5 shows MEK1 added to the surface of the sensor chip on which RAF1 is immobilized together with the test compound (A-2, A-25, J-1, E-1, M-1, N-1 or H-3).
  • FIG. 6 shows the amount of MEK1 bound to the surface of the sensor chip on which RAF1 is immobilized together with the test compound (I-1, H-4, L-1, P-1, E-7 or A-27). It is a sensorgram showing the transition over time.
  • FIG. 7 shows MEK1 added together with the test compound (A-33, A-18, N-2, A-20, A-8, E-13 or H-1) to the surface of the sensor chip on which RAF1 is immobilized. It is a sensorgram which shows the time course of the binding amount of.
  • FIG. 6 shows the amount of MEK1 bound to the surface of the sensor chip on which RAF1 is immobilized together with the test compound (I-1, H-4, L-1, P-1, E-7 or A-27). It is a sensorgram showing the transition over time.
  • FIG. 7 shows MEK1 added together with the test compound (A-33, A-18, N-2, A-20, A-8, E-13 or H-1) to the surface of the sensor chip on which RAF1 is im
  • FIG. 8 shows MEK1 added to the surface of the sensor chip on which RAF1 is immobilized together with the test compound (P-2, A-41, E-9, A-6, J-14, A-31 or A-34). It is a sensorgram which shows the time course of the binding amount of.
  • FIG. 9 shows MEK1 added together with the test compound (A-35, A-30, D-4, A-15, J-8, J-5 or A-4) to the surface of the sensor chip on which RAF1 is immobilized. It is a sensorgram which shows the time course of the binding amount of.
  • FIG. 9 shows MEK1 added together with the test compound (A-35, A-30, D-4, A-15, J-8, J-5 or A-4) to the surface of the sensor chip on which RAF1 is immobilized. It is a sensorgram which shows the time course of the binding amount of.
  • FIG. 9 shows MEK1 added together with the test compound (A-35, A-30, D-4, A-15, J-8, J-5 or A-4) to
  • FIG. 10 is a sensorgram showing the time course of the binding amount of MEK1 added together with the test compound (A-13, E-23 or J-10) on the surface of the sensor chip on which RAF1 is immobilized.
  • FIG. 11 is a sensorgram showing the time course of the binding amount of MEK1 added together with the test compound (ref-4, A-1, P-2 or A-6) on the surface of the sensor chip on which RAF1 is immobilized. be.
  • FIG. 12 shows the results of Western blotting of proteins (p-MEK, MEK, p-ERK, and ERK) extracted from A549 cells cultured in the presence of test compound (ref-5 or compound A-1). It is an electrophoretic image.
  • FIG. 13 is a graph showing changes over time in tumor volume (mean ⁇ standard deviation) in nude mice subcutaneously transplanted with the human lung cancer cell line Calu-6.
  • the halogen atom means a fluorine atom, a chlorine atom, a bromine atom or an iodine atom.
  • the C1 to 6 alkyl groups mean linear and branched alkyl groups having 1 to 6 carbon atoms.
  • the C2 to 7 alkenyl group means a linear or branched alkenyl group having 2 to 7 carbon atoms.
  • Examples thereof include vinyl group, allyl group, 1-butenyl group, 2-butenyl group, 3-butenyl group, pentenyl group, pentadienyl group, hexenyl group, hexadienyl group, heptenyl group, heptadienyl group and heptatrienyl group.
  • the C2 to 7 alkynyl group means a linear or branched alkynyl group having 2 to 7 carbon atoms.
  • the group is mentioned.
  • the C1 to 6 alkoxy group means an alkyloxy group having a linear or branched alkyl group having 1 to 6 carbon atoms. Examples thereof include a methoxy group, an ethoxy group, an n-propoxy group, an isopropoxy group, an n-butoxy group, a sec-butoxy group, a tert-butoxy group, an n-pentoxy group and an n-hexoxy group.
  • the C1 to 6 alkylthio group means an alkylthio group having a linear or branched alkyl group having 1 to 6 carbon atoms.
  • methylthio group, ethylthio group, n-propylthio group, isopropylthio group, n-butylthio group, sec-butylthio group, tert-butylthio group, n-pentylthio group and n-hexylthio group can be mentioned.
  • the C3 to 6 cycloalkyl group means a cyclic alkyl group having 3 to 6 atoms constituting the ring. It may be monocyclic or bicyclic, but unless otherwise specified, it means monocyclic. Examples of the monocyclic type include a cyclopropyl group, a cyclobutyl group, a cyclopentyl group and a cyclohexyl group. Examples of the bicyclic type include a bicyclo [1.1.1] pentanyl group and a bicyclo [2.1.1] hexyl group.
  • the C3 to 6 heterocycloalkyl group means a C3 to 6 cycloalkyl group in which at least one of the carbon atoms constituting the ring is replaced with a nitrogen atom, an oxygen atom or a sulfur atom. It may be monocyclic or bicyclic, but unless otherwise specified, it means monocyclic. Examples of the monocyclic type include a tetrahydrofuranyl group, a tetrahydropyranyl group, a pyrrolidinyl group, a piperidinyl group, a piperazinyl group and a morpholinyl group. Examples of the bicyclic type include an oxabicyclo [3.1.0] hexane-6-yl group and an azabicyclo [2.1.1] hexanyl group.
  • the unsaturated hetero 5-membered ring means an unsaturated 5-membered ring containing at least one hetero atom selected from a nitrogen atom, an oxygen atom and a sulfur atom.
  • hetero atom selected from a nitrogen atom, an oxygen atom and a sulfur atom. Examples include furan, thiophene, pyrrole, imidazole and thiazole.
  • pharmaceutically acceptable salts include, for example, inorganic acid salts such as hydrochloride, hydrobromide, hydroiodide, sulfate, phosphate; methanesulfonate, benzenesulfonic acid. , Toluene sulfonates and other sulfonates; formates, acetates, oxalates, maleates, fumarates, citrates, malates, succinates, malonates, gluconates, mandels.
  • inorganic acid salts such as hydrochloride, hydrobromide, hydroiodide, sulfate, phosphate; methanesulfonate, benzenesulfonic acid.
  • Toluene sulfonates and other sulfonates formates, acetates, oxalates, maleates, fumarates, citrates, malates, succinates, malonates, gluconates, mandels.
  • Carborates such as acid salts, benzoates, salicylates, fluoroacetates, trifluoroacetates, tartrates, propionates, glutarates; lithium salts, sodium salts, potassium salts, cesium salts, rubidium salts, etc.
  • alkali metal salts such as lithium salt, sodium salt, potassium salt, cesium salt and rubidium salt are preferable, and sodium salt and potassium salt are more preferable.
  • the pharmaceutically acceptable solvate is, for example, a solvate with water, alcohol (eg, methanol, ethanol, 1-propanol or 2-propanol), acetone, dimethylformamide or dimethylacetamide. .. It may be a solvate with a single solvent or a solvate with a plurality of solvents. Preferred solvates include, for example, hydrates.
  • the first aspect of the present disclosure provides a compound represented by the following general formula (1) or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of the compound or salt.
  • Ring A has the following general formulas (2), (3), (4) or (5) (where, the bonds with *, ** and *** are -NH-, -CONH- and, respectively. It is a group represented by -CH 2-bonded to-).
  • R 2 is a hydrogen atom, a halogen atom or a C1 ⁇ 6 alkyl group
  • R 8 and R 8 is substituted with a hydrogen atom and a C1 to 6 alkyl group (the C1 to 6 alkyl group is substituted with a halogen atom, a hydroxy group, a C1 to 6 alkoxy group, a C3 to 6 cycloalkyl group or a C3 to 6 heterocycloalkyl group.
  • R 3 is a hydrogen atom, a C1 to 6 alkyl group (the C1 to 6 alkyl group may be substituted with a halogen atom, a hydroxy group or a C1 to 6 alkoxy group), and a C3 to 6 cycloalkyl group (the C3).
  • the ⁇ 6 cycloalkyl groups may be substituted with halogen atoms or C1-6 alkyl groups) or C1-6 alkoxy groups (the C1-6 alkoxy groups are substituted with halogen atoms, hydroxy groups or C1-6 alkoxy groups). It may have been done.)
  • R 5 is a halogen atom or a C1-6 alkyl group.
  • R 6 is a hydrogen atom, a halogen atom or a C1 to 6 alkyl group
  • R 4 is a hydrogen atom, a halogen atom, a C1 to 6 alkyl group, a C2 to 7 alkenyl group, a C2 to 7 alkynyl group and a C3 to 6 cycloalkyl group.
  • R 6 and R 4 forms a together with the carbon atom bonded unsaturated heterocyclic 5-membered ring
  • R 7 is a hydrogen atom or a C1-6 alkyl group
  • R 9 is a hydrogen atom, a halogen atom or a C1-6 alkyl group.
  • the compound, salt or solvate of the first embodiment has high RAF / MEK complex stabilizing activity and is used to treat cell proliferation diseases, especially cancers (more specifically, cancers having RAS mutations, for example). Alternatively, it can be used for prevention. In addition, many of them have high MEK inhibitory activity, for example, and such compounds, salts or solvates are also suitable for cancers having, for example, RAF mutations.
  • Ring A is preferably a group represented by the general formula (2) or (4), and more preferably a group represented by the general formula (2).
  • R 2 is preferably a hydrogen atom or a halogen atom, more preferably a hydrogen atom or a fluorine atom, and further preferably a fluorine atom.
  • R 8 is preferably a hydrogen atom, a C1 to 6 alkyl group (the C1 to 6 alkyl group may be substituted with a halogen atom, a hydroxy group or a C1 to 6 alkoxy group) or a monocyclic C3 to 6 It is a cycloalkyl group (the C3 to 6 cycloalkyl group may be substituted with a C1 to 6 alkyl group), more preferably a C1 to 6 alkyl group (the C1 to 6 alkyl group is a halogen atom or C1 to C1 to).
  • a C1-4 alkyl group (the C1-4 alkyl group may be substituted with a fluorine atom or a C1-4 alkoxy group) or a cyclopropyl group (the cyclopropyl group is substituted with a C1-4 alkyl group). It may be), and more preferably it is a C1-4 alkyl group.
  • R 3 is preferably a hydrogen atom, a C1 to 6 alkyl group, a C3 to 6 cycloalkyl group or a C1 to 6 alkoxy group (the C1 to 6 alkoxy group may be substituted with a hydroxy group), and more. It is preferably a hydrogen atom, a C1-4 alkyl group, a cyclopropyl group or a C1-4 alkoxy group (the C1-4 alkoxy group may be substituted with a hydroxy group), and more preferably a hydrogen atom or a cyclopropyl group. It is a group.
  • R 5 is preferably a halogen atom, more preferably a fluorine atom.
  • R 6 is preferably a hydrogen atom, a halogen atom or a C1 to 6 alkyl group, and more preferably a hydrogen atom.
  • R 4 is preferably a halogen atom or a cyclopropyl group, more preferably an iodine atom or a cyclopropyl group.
  • R 7 is preferably a hydrogen atom or a methyl group.
  • the compound represented by the general formula (1) is preferably, for example, a compound represented by the following general formula (6).
  • R 2 is a hydrogen atom, a halogen atom or a C1 ⁇ 6 alkyl group
  • R 8 and R 8 is a hydrogen atom, a C1 to 6 alkyl group (the C1 to 6 alkyl group may be substituted with a halogen atom, a hydroxy group or a C1 to 6 alkoxy group) or a monocyclic C3 to 6 cycloalkyl. It is a group (the C3 to 6 cycloalkyl group may be substituted with a C1 to 6 alkyl group).
  • R 3 is a hydrogen atom, a C1 to 6 alkyl group, a C3 to 6 cycloalkyl group, or a C1 to 6 alkoxy group (the C1 to 6 alkoxy group may be substituted with a hydroxy group).
  • R 5 is a halogen atom or a C1-6 alkyl group.
  • R 6 is a hydrogen atom, a halogen atom or a C1-6 alkyl group, and R 4 is a halogen atom or a cyclopropyl group.
  • Examples of the compound represented by the general formula (1) include, for example. N-Cyclopropyl-3,4-difluoro-2- (2-fluoro-4-iodoanilino) -5-[[3-fluoro-2- (methylsulfamoylamino) pyridin-4-yl] methyl] benzamide ( Compound A-2), 2- (2-Fluoro-4-iodoanilino) -5-[[3-fluoro-2- (methylsulfamoylamino) pyridin-4-yl] methyl] -1-methyl-6-oxopyridine-3-carboxamide (Compound J-1), 2- (4-Cyclopropyl-2-fluoroanilino) -3,4-difluoro-5-[[3-fluoro-2- (methylsulfamoylamino) pyridin-4-yl] methyl] benzamide (Compound A) -1), N-Cyclopropy
  • N-Cyclopropyl-3,4-difluoro-2- (2-fluoro-4-iodoanilino) -5-[[3-fluoro-2- (methylsulfamoylamino) pyridin-4-yl] methyl] benzamide Compound A-2
  • Compound J-1 2- (4-Cyclopropyl-2-fluoroanilino) -3,4-difluoro-5-[[3-fluoro-2- (methylsulfamoylamino) pyridin-4-yl
  • a second aspect of the present disclosure is a RAF / containing a compound represented by the following general formula (11) or a pharmaceutically acceptable salt thereof or a pharmaceutically acceptable solvate of the compound or salt as an active ingredient.
  • a stabilizer for the MEK complex is provided.
  • R 2 is a hydrogen atom, a halogen atom or a C1 ⁇ 6 alkyl group
  • X 7 is-(CH 2 ) m -or -O- and m is 1, 2 or 3.
  • R 3 is a hydrogen atom, a C1 to 6 alkyl group (the C1 to 6 alkyl group may be substituted with a halogen atom, a hydroxy group or a C1 to 6 alkoxy group), and a C3 to 6 cycloalkyl group (the C3).
  • the ⁇ 6 cycloalkyl groups may be substituted with halogen atoms or C1-6 alkyl groups) or C1-6 alkoxy groups (the C1-6 alkoxy groups are substituted with halogen atoms, hydroxy groups or C1-6 alkoxy groups). It may have been done.)
  • R 5 is a hydrogen atom, a halogen atom or a C1-6 alkyl group.
  • R 6 is a hydrogen atom, a halogen atom or a C1 to 6 alkyl group
  • R 4 is a hydrogen atom, a halogen atom, a C1 to 6 alkyl group, a C2 to 7 alkenyl group, a C2 to 7 alkynyl group and a C3 to 6 cycloalkyl group. or is a C1 ⁇ 6 alkylthio group, or R 6 and R 4 forms a together with the carbon atom bonded unsaturated heterocyclic 5-membered ring
  • R 7 is a hydrogen atom or a C1-6 alkyl group
  • R 9 is a hydrogen atom, a halogen atom or a C1-6 alkyl group.
  • the compound, salt or solvate of the second embodiment has high RAF / MEK complex stabilizing activity and is used to treat cell proliferation diseases, especially cancers (more specifically, cancers having RAS mutations, for example). Alternatively, it can be used for prevention. In addition, many of them have high MEK inhibitory activity, for example, and such compounds, salts or solvates are also suitable for cancers having, for example, RAF mutations.
  • Ring A is preferably a group represented by the general formula (2) or (4), and more preferably a group represented by the general formula (2).
  • R 2 is preferably a hydrogen atom or a halogen atom, more preferably a hydrogen atom or a fluorine atom, and further preferably a fluorine atom.
  • X 7 is preferably -CH 2- .
  • R 8 is preferably a hydrogen atom, a C1 to 6 alkyl group (the C1 to 6 alkyl group may be substituted with a halogen atom, a hydroxy group or a C1 to 6 alkoxy group) or a monocyclic C3 to 6 It is a cycloalkyl group (the C3 to 6 cycloalkyl group may be substituted with a C1 to 6 alkyl group), more preferably a C1 to 6 alkyl group (the C1 to 6 alkyl group is a halogen atom or C1 to C1 to).
  • a C1-4 alkyl group (the C1-4 alkyl group may be substituted with a fluorine atom or a C1-4 alkoxy group) or a cyclopropyl group (the cyclopropyl group is substituted with a C1-4 alkyl group). It may be), and more preferably it is a C1-4 alkyl group.
  • R 3 is preferably a hydrogen atom, a C1 to 6 alkyl group, a C3 to 6 cycloalkyl group or a C1 to 6 alkoxy group (the C1 to 6 alkoxy group may be substituted with a hydroxy group), and more. It is preferably a hydrogen atom, a C1-4 alkyl group, a cyclopropyl group or a C1-4 alkoxy group (the C1-4 alkoxy group may be substituted with a hydroxy group), and more preferably a hydrogen atom or a cyclopropyl group. It is a group.
  • R 5 is preferably a halogen atom or a C1 to 6 alkyl group, more preferably a halogen atom, and even more preferably a fluorine atom.
  • R 6 is preferably a hydrogen atom, a halogen atom or a C1 to 6 alkyl group, and more preferably a hydrogen atom.
  • R 4 is preferably a halogen atom or a cyclopropyl group, more preferably an iodine atom or a cyclopropyl group.
  • R 7 is preferably a hydrogen atom or a methyl group.
  • the compound represented by the general formula (11) is preferably, for example, a compound represented by the following general formula (6).
  • R 2 is a hydrogen atom, a halogen atom or a C1 ⁇ 6 alkyl group
  • R 8 and R 8 is a hydrogen atom, a C1 to 6 alkyl group (the C1 to 6 alkyl group may be substituted with a halogen atom, a hydroxy group or a C1 to 6 alkoxy group) or a monocyclic C3 to 6 cycloalkyl. It is a group (the C3 to 6 cycloalkyl group may be substituted with a C1 to 6 alkyl group).
  • R 3 is a hydrogen atom, a C1 to 6 alkyl group, a C3 to 6 cycloalkyl group, or a C1 to 6 alkoxy group (the C1 to 6 alkoxy group may be substituted with a hydroxy group).
  • R 5 is a halogen atom or a C1-6 alkyl group.
  • R 6 is a hydrogen atom, a halogen atom or a C1-6 alkyl group, and R 4 is a halogen atom or a cyclopropyl group.
  • Examples of the compound represented by the general formula (11) include, for example. N-Cyclopropyl-3,4-difluoro-2- (2-fluoro-4-iodoanilino) -5-[[3-fluoro-2- (methylsulfamoylamino) pyridin-4-yl] methyl] benzamide ( Compound A-2), 2- (2-Fluoro-4-iodoanilino) -5-[[3-fluoro-2- (methylsulfamoylamino) pyridin-4-yl] methyl] -1-methyl-6-oxopyridine-3-carboxamide (Compound J-1), 2- (4-Cyclopropyl-2-fluoroanilino) -3,4-difluoro-5-[[3-fluoro-2- (methylsulfamoylamino) pyridin-4-yl] methyl] benzamide (Compound A) -1), N-Cycloprop
  • N-Cyclopropyl-3,4-difluoro-2- (2-fluoro-4-iodoanilino) -5-[[3-fluoro-2- (methylsulfamoylamino) pyridin-4-yl] methyl] benzamide Compound A-2
  • Compound J-1 2- (4-Cyclopropyl-2-fluoroanilino) -3,4-difluoro-5-[[3-fluoro-2- (methylsulfamoylamino) pyridin-4-yl
  • a third aspect of the present disclosure provides a compound represented by the following general formula (1) or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of the compound or salt.
  • a fourth aspect of the present disclosure provides a MEK inhibitor containing such a compound, salt or solvate as an active ingredient.
  • Ring A is represented by the following general formula (2), (3) or (4) (wherein, *, respectively ** and a bond that is attached *** -NH -, - CONH- and -CH 2 - It is a group represented by) and is bonded to.
  • R 2 is a hydrogen atom, a halogen atom or a C1 ⁇ 4 alkyl group
  • R 8 and R 8 may be substituted with a C1-4 alkyl group (the C1-4 alkyl group may be substituted with a halogen atom, a hydroxy group, a C1-4 alkoxy group, a C3-6 cycloalkyl group or a C3-6 heterocycloalkyl group. )
  • C3 to 6 cycloalkyl groups the C3 to 6 cycloalkyl groups may be substituted with C1 to 4 alkyl groups).
  • R 3 is a hydrogen atom, a C3 to 6 cycloalkyl group or a C1 to 6 alkoxy group.
  • R 5 is a halogen atom
  • R 6 is a hydrogen atom and
  • R 4 is a halogen atom or a C3-6 cycloalkyl group.
  • R 7 is a C1-4 alkyl group
  • R 9 is a hydrogen atom.
  • the compounds, salts or solvates of the third or fourth aspect have high MEK inhibitory activity and treat or prevent cell proliferation diseases, especially cancers (more specifically, cancers with, for example, RAF mutations). Can be used for.
  • Examples of the compound of the third or fourth aspect include, for example, in terms of MEK inhibitory activity and metabolic stability, for example.
  • 2- (4-Cyclopropyl-2-fluoroanilino) -3,4-difluoro-5-[[3-fluoro-2- (methylsulfamoylamino) pyridin-4-yl] methyl] benzamide (Compound A) -1), (+/-)-3,4-difluoro-5-[[3-fluoro-2- (2-hydroxypropylsulfamoylamino) pyridin-4-yl] methyl] -2- (2-fluoro-4-yl] Iodoanilino) Benzamide (Compound A-17), 3,4-Difluoro-2- (2-fluoro-4-iodoanilino) -5-[[3-fluoro-2- (oxetane-3-ylmethylsulfamoylamino) pyridin
  • Boc tert-butoxycarbonyl COMU: (1-cyano-2-ethoxy-2-oxoethylideneaminooxy) dimethylamino-morpholino-carbenium hexafluorophosphate
  • DBU diazabicycloundecene
  • DCC N, N'- Dicyclohexylcarbodiimide
  • DCM dichloromethane
  • DIPEA N, N-diisopropylethylamine
  • DMA N, N-dimethylacetamide
  • DMF N, N-dimethylformamide
  • DMSO dimethylsulfoxide
  • EDC 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide
  • EDC HCl 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride
  • EtOH Ethanol HATU: O- (7-azabenzotrifluoride
  • R a represents, for example, 4-methylphenyl group or a 2-nitrophenyl group
  • R b represents an example Boc group or a 2,4-dimethoxybenzyl group.
  • Step 1-1 The presence of S N Ar reaction base with aniline derivatives 1b and fluorobenzene derivatives 1a, reacting the aniline derivative 1b fluorobenzene derivative 1a.
  • the base include an organic lithium reagent, and lithium bis (trimethylsilyl) amide and lithium diisopropylamide are preferable.
  • the solvent include polar aprotic solvents such as THF, 1,4-dioxane, and NMP, and THF is preferable.
  • Process 1-2 Methylation of Benzoic Acid Derivative 1c
  • the benzoic acid derivative 1c is reacted with a methylation reagent.
  • the methylation reagent include a diazomethane derivative, and diazomethyltrimethylsilane is preferable.
  • the solvent include alcohol, a non-polar solvent and a mixed solvent thereof, and a mixed solvent of toluene and methanol and a mixed solvent of THF and methanol are preferable.
  • Process 1-3 Hydrazonization of the aldehyde derivative 1d
  • the aldehyde derivative 1d is reacted with arylsulfonyl hydrazide.
  • arylsulfonyl hydrazide include methylbenzenesulfonyl hydrazide and nitrobenzenesulfonylhydrazide, and 4-methylbenzenesulfonylhydrazide and 2-nitrobenzenesulfonylhydrazide are preferable.
  • the solvent include polar solvents such as alcohol, and methanol and ethanol are preferable.
  • Step 1-4 Coupling of hydrazone derivative 1e and arylboronic acid derivative 1f
  • the hydrazone derivative 1e is reacted with the arylboronic acid derivative 1f in the presence of a base.
  • the base include carbonate and amine, and potassium carbonate and DIPEA are preferable.
  • the solvent include polar solvents such as 1,4-dioxane, DMF, NMP, and THF, and 1,4-dioxane is preferable.
  • the reaction temperature is preferably 80 ° C. or higher.
  • Step 1-5 Deprotection of 1 g of Methyl benzoate derivative
  • the protecting group R b is eliminated by placing 1 g of the methyl benzoate derivative under acidic conditions.
  • the acid include sulfuric acid, hydrochloric acid, methanesulfonic acid and trifluoroacetic acid, and trifluoroacetic acid is preferable.
  • the solvent include alcohol and non-polar solvents such as DCM, and DCM is preferable.
  • Step 1-6 Hydrolysis of ester derivative 1h
  • the ester derivative 1h is reacted with a hydroxide.
  • the hydroxide include lithium hydroxide, potassium hydroxide and sodium hydroxide, and lithium hydroxide is preferable.
  • the solvent include alcohol, a polar solvent such as THF, water, and a mixed solvent thereof, and an aqueous solution of THF is preferable.
  • Step 1-7 Amidation of Benzoic Acid Derivative 1i
  • the benzoic acid derivative 1i is reacted with the corresponding amine or amine hydrochloride.
  • the corresponding amine or amine hydrochloride may have a Boc group.
  • the condensing agent include DCC, EDC or EDC / HCl, HATU, COMU, and propylphosphonic anhydride (cyclic trimmer), and for example, HOOBt or HOAt may be further added as appropriate.
  • a combination of EDC or EDC / HCl and HOOBt, or HATU is used.
  • a base such as DIPEA or triethylamine may be used in addition to the condensing agent, and DIPEA is preferable as the base.
  • the solvent include polar solvents such as DMF, DMA, NMP, methanol and ethanol, and mixed solvents thereof, and DMF is preferable.
  • Step 1-8 Sulfamides or sulfonamides of amine derivatives 1j, 1ja or 1jb Sulfamides: In the presence of a base, the amine derivatives 1j, 1ja or 1jb are reacted with the corresponding sulfamoyl chloride or 4-nitrophenyl sulfamic acid.
  • the corresponding sulfamoyl chloride or 4-nitrophenyl sulfamic acid may have a Boc group.
  • the base include amines, with pyridine, triethylamine, DIPEA and imidazole being preferred.
  • the solvent examples include polar solvents such as DMF, DMA, NMP, THF, 1,4-dioxane, acetonitrile and pyridine, non-polar solvents such as dichloromethane and dichloroethane, and mixed solvents thereof. THF and dichloromethane are preferred.
  • Sulfonamide In the presence of a base, the amine derivatives 1j, 1ja or 1jb are reacted with the corresponding sulfonyl chloride.
  • the base include amines, with pyridine, triethylamine, DIPEA and imidazole being preferred.
  • the solvent include polar solvents such as DMF, DMA, NMP, THF, 1,4-dioxane, acetonitrile and pyridine, non-polar solvents such as dichloromethane and dichloroethane, and mixed solvents thereof, and dichloromethane and pyridine are used. preferable.
  • Steps 1-9-1 De-Bocization of Sulfamide or Sulfonamide Derivative 1k1
  • the Boc group is eliminated by placing the compound 1k1 under acidic conditions.
  • the acid include sulfuric acid, hydrochloric acid, methanesulfonic acid and trifluoroacetic acid.
  • de-Boc may be performed by generating an acid in alcohol, for example, chlorotrimethylsilane (TMSCl).
  • TMSCl chlorotrimethylsilane
  • the solvent include alcohol and non-polar solvents such as DCM.
  • TMSCl chlorotrimethylsilane
  • DCM non-polar solvents
  • the combination of the acid and the solvent for example, a combination of TMSCl and 2,2,2-trifluoroethanol or a combination of trifluoroacetic acid and DCM is preferable.
  • Step 1-9-2 Alkylation, alkenylation, alkynylation or thioetherification of sulfamide or sulfonamide derivative 1k1 If R 4 or R 5 of sulfamide or sulfonamide derivative 1k1 is halogen, for example, alkylation, alkenylation, alkynylation or alkynylation by the following method. Thioetherification can be performed.
  • Method 1 Alkylation or alkenylation by Suzuki-Miyaura cross-coupling: In the presence of Pd, compound 1k1 is reacted with the corresponding boronic acid, boronic acid ester or boronate.
  • boronic acid boronic acid ester or boronate.
  • the base include inorganic salts such as carbonate and hydroxide, and amines such as triethylamine and DIPEA, and sodium carbonate, potassium carbonate and triethylamine are preferable.
  • the solvent examples include polar solvents such as THF, 1,4-dioxane, DMF, DMA, NMP, methanol, ethanol, 2-propanol, and water, and mixed solvents thereof, which include THF and 2-propanol.
  • a mixed solvent and a mixed solvent of THF and water are preferable.
  • Pd and ligand include Chem. Rev. 1995, vol. 95, no. 7, p. 2457, ACC. Chem. Res. , Vol. 40, p. 275, and ACC. Chem. Res. , Vol. 41, p.
  • the ones described in 1461 are mentioned, and PdCl 2 (PPh 3 ) 2 , Pd (PPh 3 ) 4 , and [1,1'-bis (diphenylphosphino) ferrocene] palladium (II) dichloride are preferable.
  • the reaction temperature is preferably 80 ° C. or higher.
  • Method 2 (alkylation or alkenylation by Negishi cross-coupling): In the presence of Pd or Ni, compound 1k1 is reacted with the corresponding organozinc reagent.
  • organozinc reagent for example, Tetrahedron. 1992, vol. 48, no. 44, p. 9577 or Aldrichimica Acta. 2005, vol. 38, p. It can be carried out by the method described in 71.
  • the solvent include polar solvents such as THF, 1,4-dioxane, DMF, DMA, and NMP, and mixed solvents thereof, and THF is preferable.
  • Pd and Ni include Tetrahedron. 1992, vol. 48, no. 44, p. 9577 and Aldrichimica Acta. 2005, vol.
  • Method 3 Alkynylation by Sonogashira cross-coupling: In the presence of Pd and Cu, compound 1k1 is reacted with the corresponding alkyne.
  • the corresponding alkyne may have a silyl group, for example trimethylsilylacetylene.
  • the base include amines such as triethylamine, DIPEA, DBU and piperidine, and inorganic bases such as NaOAc, and triethylamine and DIPEA are preferable.
  • Examples of the Pd catalyst include PdCl 2 (PPh 3 ) 2 , Pd (PPh 3 ) 4 , [1,1'-bis (diphenylphosphino) ferrocene] palladium (II) dichloride, Pd (OAc) 2 , and Pd. 2 (dba) 3 is mentioned, and PdCl 2 (PPh 3 ) 2 , Pd (PPh 3 ) 4 , and [1,1'-bis (diphenylphosphino) ferrocene] palladium (II) dichloride are preferable.
  • Examples of Cu include copper iodide, copper bromide and copper chloride, and copper iodide is preferable.
  • Examples of the solvent include polar solvents such as THF, 1,4-dioxane, DMF, DMA, NMP, DMSO, methanol, ethanol and 2-propanol, and mixed solvents thereof, and THF is preferable.
  • Method 4 In the presence of Pd, compound 1k1 is reacted with the corresponding mercaptan or mercaptan salt.
  • the base include amines such as triethylamine, DIPEA, DBU and piperidine, and triethylamine and DIPEA are preferable.
  • the Pd catalyst include 0-valent Pd complexes such as Pd (PPh 3 ) 4 , [(4,5-bis (diphenylphosphino) -9,9-dimethylxanthene) -2- (2'). -Amino-1,1'-biphenyl)] Palladium (II) methanesulfonate is preferred.
  • solvent examples include polar solvents such as THF, 1,4-dioxane, DMF, DMA, NMP, DMSO, methanol, ethanol and 2-propanol, and mixed solvents thereof, and 1,4-dioxane is preferable. ..
  • Step 1-10 Bromination or chlorination of the amine derivative 1j
  • R 4 or R 5 of the amine derivative 1j is a halogen
  • bromination or chlorination can be performed by reacting the compound 1j with copper bromide or copper chloride.
  • the solvent include polar solvents such as THF, 1,4-dioxane, DMF, DMA, and NMP, and DMF is preferable.
  • Step 1-11 If R 3 in TBS amine derivative 1j of the amine derivative 1j has hydroxy groups, the presence of a base, it is possible to perform TBS by reacting it with a compound 1j tert-butyldimethylchlorosilane (TBSCl).
  • TBSCl tert-butyldimethylchlorosilane
  • the base include bases such as triethylamine, DIPEA, and imidazole, and triethylamine is preferable.
  • the solvent include polar solvents such as THF, 1,4-dioxane, DMF, DMA, and NMP, and DMF is preferable.
  • Step 1-12-1 If de-TBS sulfamide or where R 3 of the sulfonamide derivatives 1k2 sulfamide or sulfonamide derivatives 1k2 has a TBS group, desorbed the TBS group by reacting the compound 1k2 and tetrabutylammonium fluoride.
  • the solvent include polar solvents such as THF, 1,4-dioxane, and DMF, and THF is preferable.
  • Step 1-12-2 Desilylation of Sulfamide or Sulfonamide Derivative 1k2
  • R 4 or R 5 of sulfamide or sulfonamide derivative 1k2 has a silyl group
  • the silyl group is eliminated by reacting compound 1k2 with a base.
  • the base include carbonate, and potassium carbonate is preferable.
  • the solvent include alcohols such as methanol and ethanol, and methanol is preferable.
  • Step 2-1 Sulfamide formation or sulfonamide formation of the amine derivative 1h is carried out in the same manner as in Step 1-8.
  • Step 2-2 Hydrolysis of the ester derivative 2a is carried out in the same manner as in Step 1-6.
  • Step 2-3 The amidation of the benzoic acid derivative 2b is carried out in the same manner as in Step 1-7. Prior to amidation, optionally de-Boc, alkylation, alkenylation, alkynylation, thioetherification, bromination or chlorination of the benzoic acid derivative 2b is performed in steps 1-9-1, 1-9-2 or It may be carried out in the same manner as 1-10.
  • Step 3-1 Hydrazonization of the aldehyde derivative 1c is carried out in the same manner as in Step 1-3.
  • Step 3-2 The amidation of the benzoic acid derivative 3a is carried out in the same manner as in Step 1-7.
  • Step 3-3 Coupling of the hydrazone derivative 3b with the arylboronic acid derivative 1f, desorption of the protecting group Rb , and sulfamidelation or sulfonamide formation of the amine derivative were carried out in this order in steps 1-4, 1-5 and 1-8, respectively. Do the same.
  • Step 4-1 Alkylation of Compound 4a
  • a base examples include phosphates and metal alkoxides such as sodium tert-butoxide, with tripotassium phosphate being preferred.
  • potassium iodide or tetrabutylammonium iodide may be added in order to accelerate the reaction, and tetrabutylammonium iodide is preferable as such an additive.
  • the solvent include polar solvents such as NMP and 1,3-dimethyl-2-imidazolidinone, and 1,3-dimethyl-2-imidazolidinone is preferable.
  • the reaction temperature is preferably 40 ° C. or higher.
  • the starting compound or reagent may form a salt or solvate as long as the desired reaction is not inhibited.
  • the compound of the present disclosure When the compound of the present disclosure is obtained as a free form, it can be converted into a pharmaceutically acceptable salt or solvate form according to a conventional method. Further, when the compound of the present disclosure is obtained in the form of a pharmaceutically acceptable salt or solvate, it can be converted into a free form according to a conventional method.
  • Isolation or purification of the compounds of the present disclosure can be carried out using, for example, distillation, recrystallization or chromatography. Also, if isomers (eg, enantiomers, diastereomers or constitutive isomers) are present, their isolation or purification can be, for example, recrystallization, diastereomeric salting, enzymatic division or chromatography (eg,). It can be performed using thin layer chromatography, column chromatography, high performance liquid chromatography or gas chromatography).
  • the present disclosure provides a pharmaceutical composition containing the compound, salt or solvate of any of the first to fourth aspects as an active ingredient.
  • the present disclosure comprises a cell proliferation disease, particularly a therapeutic or prophylactic agent for cancer, which contains the compound, salt or solvate of any one of the first to fourth aspects as an active ingredient. offer.
  • the subject to which the compound, salt or solvate of the present disclosure is administered is an animal, preferably a mammal (eg, mouse, rat, rabbit, dog, monkey (eg, cynomolgus monkey) or human), particularly preferably a human.
  • a mammal eg, mouse, rat, rabbit, dog, monkey (eg, cynomolgus monkey) or human
  • Humans may be adults (18 years or older) or children (under 18 years). Children are preferably, for example, 6 months or older.
  • the dose and administration interval depend on the degree of symptoms, the age and weight of the subject to be administered, the presence or absence of concomitant drugs, the administration method, and the like. It can be determined as appropriate.
  • the administration subject is a human
  • an amount of 0.00001 to 5000 mg, preferably 0.01 to 100 mg per 1 kg of body weight is usually administered once a day to 3 weeks.
  • the above amount may be administered in 2 to 4 divided doses.
  • Examples of the administration method to the subject include systemic administration such as oral administration, rectal administration, intravenous administration, intramuscular administration, subcutaneous administration, intratank administration, intravaginal administration, intraperitoneal administration, intravesical administration, and inhalation administration. And topical administration with an ointment, gel or cream, but oral administration is preferred.
  • the compound, salt or solvate of the present disclosure is usually used by being formulated into a certain formulation (dosage form).
  • formulations include, for example, tablets, capsules, granules, powders, fine granules, pills, and aqueous or non-aqueous solutions and suspensions. Solutions and suspensions can be packed and stored in containers suitable for subdivision into individual doses.
  • additives include, for example, excipients, lubricants (coatings), binders, disintegrants, stabilizers, flavoring agents, bases, dispersants, diluents, surfactants, and emulsifiers. Can be mentioned.
  • excipients examples include starch (starch, potato starch, corn starch, etc.), lactose, crystalline cellulose, and calcium hydrogen phosphate.
  • lubricant examples include ethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, shellac, talc, carnauba wax, and paraffin.
  • binder examples include polyvinylpyrrolidone and macrogol, as well as compounds similar to the above-mentioned excipients.
  • disintegrant examples include chemically modified starches and celluloses such as croscarmellose sodium, carboxymethyl starch sodium, and crosslinked polyvinylpyrrolidone, as well as compounds similar to the above excipients.
  • stabilizers include paraoxybenzoic acid esters such as methylparaben and propylparaben; benzalkonium chloride; phenols such as phenol and cresol; thimerosal; dehydroacetic acid; and sorbic acid.
  • flavoring and flavoring agent examples include commonly used sweeteners, acidulants and flavors.
  • Examples of the base include fats such as pork fat; vegetable oils such as olive oil and sesame oil; higher alcohols such as stearyl alcohol and cetanol; animal oils; lanolic acid; petrolatum; paraffin; bentonite; glycerin; and glycol oil. ..
  • Dispersants include, for example, cellulose derivatives (eg, gum arabic, tragant, and methylcellulose), polyester stearate, sorbitan sesquioleate, aluminum monostearate, sodium alginate, polysorbates, and sorbitan fatty acid esters. ..
  • solvent or diluent in the liquid preparation examples include phenol, chlorocresol, purified water, and distilled water.
  • surfactant or emulsifier examples include polysorbate 80, polyoxyl 40 stearate, and lauromacrogol.
  • the preferable content ratio of the compound, salt or solvate of the present disclosure in the formulation varies depending on the dosage form, but is usually 0.01 to 100% by weight based on the total weight of the formulation.
  • Cell-proliferative diseases treated or prevented using the compounds, salts or solvates of the present disclosure include cancer, rheumatism and inflammation, which are preferably cancers.
  • Cancers include, for example, leukemia (acute myeloid leukemia, acute lymphocytic leukemia, chronic myeloid leukemia, chronic lymphocytic leukemia, etc.), malignant lymphoma (Hodgkin's disease, non-Hodgkin's lymphoma, etc.), multiple myeloma, myelopathy.
  • leukemia acute myeloid leukemia, acute lymphocytic leukemia, chronic myeloid leukemia, chronic lymphocytic leukemia, etc.
  • malignant lymphoma Hodgkin's disease, non-Hodgkin's lymphoma, etc.
  • multiple myeloma myelopathy.
  • Blood and lymph cancers such as plastic syndrome; cancers of the central nervous system such as brain tumors and gliomas; and head and neck cancers (pharyngeal cancer, laryngeal cancer, tongue cancer, etc.), esophageal cancer, gastric cancer, colon cancer (cementitis) Cancer, colon cancer, rectal cancer, etc.), lung cancer (small cell cancer, non-small cell cancer, etc.), thyroid cancer, breast cancer, cholecyst cancer, pancreatic cancer, liver cancer, prostate cancer, ovarian cancer, uterine cancer (endometrial cancer, Cervical cancer, etc.), testicular cancer, renal cell cancer, bladder cancer, renal pelvis / urinary tract cancer, malignant melanoma, skin cancer (basal cell cancer, spinous cell cancer, extramammary Paget's disease, Mercel cell cancer, sweat adenocarcinoma)
  • solid cancers such as apocrine adenocarcinoma or eclin adenocarcinoma
  • Cancer may have a gene mutation, no gene mutation, or it may be unknown whether it is one of them.
  • genes that cause mutations include EGFR, FGFR, ALK, ROS1, PI3K, BRAF, HRAS, KRAS and NRAS.
  • the cancer for example, a cancer having a RAS mutation is preferable, and for example, a solid cancer having a KRAS mutation (particularly non-small cell lung cancer) is particularly preferable. preferable. In one embodiment, it is also used for cancers having RAF mutations, particularly cancers having RAF mutations and RAS mutations.
  • a cancer having a RAF mutation is preferable, and for example, a solid cancer having a BRAF mutation (particularly malignant melanoma) is particularly preferable. ..
  • the mass spectrum data includes a single quadrupole mass spectrometer (LCMS-2020) with ultra-high performance liquid chromatography (Nexera UC) manufactured by Shimadzu Corporation or an accuracy ultra-high performance liquid chromatography (UPLC or UPLC I-Class) manufactured by Waters. Obtained using a single quadrupole mass analyzer (SQD or SQD2).
  • LCMS-2020 single quadrupole mass spectrometer
  • Nexera UC ultra-high performance liquid chromatography
  • UPLC or UPLC I-Class ultra-high performance liquid chromatography
  • the microwave reaction was carried out using an Initiator manufactured by Biotage. A snap cap reaction vial was used for the microwave reaction.
  • room temperature means a temperature of about 20 ° C to about 25 ° C.
  • production example of compound A-1 means production example A-1-1
  • production example of compound a9 means production example a9-1
  • Tetrakis (triphenylphosphine) palladium (0) (11.2 mg, 9.68 ⁇ mol) and 0.5 M cyclopropyl zinc bromide (1.94 mL, 0.969 mmol) were added to an anhydrous THF solution (1.9 mL) of 194 mmol).
  • Ethyl acetate (5 mL) was added to the reaction mixture, and the mixture was filtered through Celite and washed with ethyl acetate (3 mL). The filtrate was washed with water and saturated brine, the organic layer was dried over anhydrous sodium sulfate, the desiccant was filtered off, and the mixture was concentrated under reduced pressure.
  • tert-butoxyamine hydrochloride (68.1 mg, 0.542 mmol) and DIPEA (0.95 mL, 0.542 mmol) were added, and the mixture was stirred at room temperature for 1.5 hours.
  • the reaction mixture was purified by reverse phase column chromatography (0.1% formic acid aqueous solution / 0.1% formic acid acetonitrile solution) to give the title compound (89 mg, 84%) as a colorless solid.
  • LCMS m / z 589 [M + H] + HPLC retention time: 0.77 minutes (analytical condition C)
  • Tris (dibenzylideneacetone) dipalladium (0) (14.9 g, 16.3 mmol) and toluene (540 mL) were added, and the mixture was further degassed under reduced pressure and replaced with nitrogen.
  • the mixture was heated to an outside temperature of 120 ° C. under a nitrogen atmosphere and stirred for 7 hours.
  • the outside temperature was cooled to room temperature, the reaction mixture was filtered and washed with toluene (450 mL).
  • Activated carbon (9.00 g, 749 mmol) was added to the filtrate, and the mixture was stirred at room temperature for 1 hour.
  • Example A-1b a seed crystal of the sodium salt of compound A-1 (Sample A-1b described below), stirred at room temperature for 1 hour, and then ethanol (15.1 mL). ) was added, and the mixture was stirred at room temperature for 4 hours. Then, ethanol (15.1 mL) was further added, and the mixture was stirred at room temperature for 4 hours to obtain a sodium salt (2.74 g) of compound A-1 as powdery crystals (Sample A-1a (FormI)).
  • sample A-1b To compound A-1 (53.6 mg), a 20% sodium ethoxide ethanol solution (0.054 mL) and methyl isobutyl ketone (0.161 mL) were added, and the mixture was stirred at room temperature for 30 minutes. Methyl isobutyl ketone (0.161 mL) was then added and stirred at 60 ° C. for 4 days. Then, DMSO (0.054 mL) was added, and the mixture was stirred at 60 ° C. for 5 hours to obtain a sodium salt (25.6 mg) of compound A-1 as powdery crystals (Sample A-1b).
  • Sample A-1a (FormI)
  • Sample A-1b and Sample A-1c were subjected to powder X-ray diffraction measurement under the following conditions.
  • Measuring device SmartLab, D / Tex Ultra detector (manufactured by Rigaku)
  • Anti-cathode Cu Tube voltage: 45kV Tube current: 200mA Sampling width: 0.02 °
  • FIGS. 1 to 3 The results of powder X-ray diffraction measurement are shown in FIGS. 1 to 3.
  • FIG. 1 shows a powder X-ray diffraction pattern of sample A-1a (FormI).
  • FIG. 2 shows a powder X-ray diffraction pattern of sample A-1b.
  • FIG. 3 shows a powder X-ray diffraction pattern of sample A-1c.
  • the horizontal axis (X-axis) represents the diffraction angle 2 ⁇ (°)
  • the vertical axis (Y-axis) represents the diffraction intensity.
  • Measuring device Dionex ICS-1600, AS-AP (manufactured by Thermo Fisher Scientific) Column: Dionex IonPac CG16 (5 x 50 mm) / CS16 (5 x 250 mm) (manufactured by Thermo Fisher Scientific) Eluent: 30 mmol / L methanesulfonic acid solution Suppressor: Dionex CERS-500 4 mm, 88 mA (manufactured by Thermo Fisher Scientific) Column temperature: 40 ° C Eluent flow rate: 1.00 mL / min Sample injection volume: 10 ⁇ L Detector: Electrical conductivity detector Sample treatment: Sample A-1a is suspended in a 20 mmol / L methanesulfonic acid solution at a concentration of 0.5 mg / mL, and shaken for 17 hours to extract sodium ions and supernatant. Was measured.
  • Compound B-8 3,4-Difluoro-2- (2-fluoro-4-iodoanilino) -5-[[3-fluoro-2- (propylsulfonylamino) pyridin-4-yl] methyl] benzamide 5-[(2-Amino-3-fluoropyridin-4-yl) methyl] -3,4-difluoro-2- (2-) under the same conditions as in the production examples of Compound A-25, Compound b2 and Compound a8.
  • the title compound was synthesized from methyl benzoate (compound a6) and the corresponding sulfonyl chloride.
  • Compound B-12 2- (2-Chloro-4-iodoanilino) -N-cyclopropyl-5-[[2- (cyclopropylsulfamoylamino) -3-fluoropyridin-4-yl] methyl] -3,4-difluorobenzamide 5-[(2-Amino-3-fluoropyridin-4-yl) methyl] -2- (2-chloro-4-iodoanilino) under the same conditions as in the production examples of Compound A-1, Compound b2 and Compound a8.
  • Compound B-13 2- (2-Chloro-4-iodoanilino) -5-[[2- (cyclopropylsulfamoylamino) -3-fluoropyridin-4-yl] methyl] -3,4-difluoro-N-[(2) -Methylpropan-2-yl) oxy] benzamide 5-[(2-Amino-3-fluoropyridin-4-yl) methyl] -2- (2-chloro-4-iodoanilino) under the same conditions as in the production examples of Compound A-1, Compound b2 and Compound a8.
  • Compound B-16 5-[[2- (Ethylsulfonylamino) -3-fluoropyridin-4-yl] methyl] -3,4-difluoro-2- (2-fluoro-4-iodoanilino) -N-methoxybenzamide 5-[(2-Amino-3-fluoropyridin-4-yl) methyl] -3,4-difluoro-2- (2-) under the same conditions as in the production examples of Compound A-25, Compound b2 and Compound a12. The title compound was synthesized from methyl benzoate (compound a6) and the corresponding sulfonyl chloride.
  • Lithium hydroxide monohydrate (7.9 mg, 0.19 mmol) was added to a mixed solution of THF (0.7 mL) and water (0.3 mL) of 038 mmol), and the mixture was stirred at room temperature for 2 hours.
  • the reaction mixture was concentrated under reduced pressure, 1M hydrochloric acid (0.76 mL) was added, and the mixture was further concentrated under reduced pressure.
  • HOOBt (9.3 mg, 0.057 mmol) and EDC HCl (10.9 mg, 0.057 mmol) were added to an anhydrous DMF solution (0.3 mL) of the obtained mixture, and the mixture was stirred at room temperature for 3 hours.
  • Compound G-8 2- (4-Cyclopropyl-2-fluoroanilino) -5-[[2- (ethylsulfonylamino) -3-fluoropyridin-4-yl] methyl] -3,4-difluoro-N-methoxybenzamide
  • the title compound was synthesized from methyl benzoate (compound a6) and the corresponding sulfonyl chloride.
  • reaction mixture was added to a solution of 2,3,4-trifluorobenzoic acid (1.50 g, 8.52 mmol) in THF (9.0 mL) at ⁇ 78 ° C., stirred for 10 minutes, then anhydrous DMF (0.759 mL, 0.759 mL, 9.80 mmol) was added, and the mixture was stirred at 0 ° C. for 2 hours.
  • a THF solution (30 mL) of benzo [b] thiophenone-5-amine (1.65 g, 11.1 mmol) was cooled to ⁇ 78 ° C.
  • reaction mixture was added to an anhydrous THF solution (15 mL) of 1,2,3-trifluoro-4-[(4-methoxyphenyl) methoxy] benzene (compound h9, 3.00 g, 11.2 mmol) at ⁇ 78 ° C.
  • the mixture was stirred for 3 hours and then for 30 minutes while injecting carbon dioxide gas.
  • 1M Hydrochloric acid 60 mL was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with water, dried over anhydrous sodium sulfate, the desiccant was filtered off, and the mixture was concentrated under reduced pressure.
  • reaction mixture was washed with 1M hydrochloric acid and saturated brine, and the organic layer was dried over anhydrous sodium sulfate. After removing the desiccant by filtration, the filtrate was concentrated under reduced pressure to give the title compound (4.0 g, 33%) as a white solid.
  • the desiccant was removed by filtration, concentrated under reduced pressure, and the obtained residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate) to give the title compound (1.50 g, 61%) as a white solid.
  • RAF1 (Carna Biosciences) fused with a GST tag was immobilized on the surface of Sensor Chip CM5 (GE Healthcare) using Anti-GST Antibody (GE Healthcare). Then, a running buffer (blank), a 40 nM MEK1 solution, or a mixed solution of 40 nM MEK1 and a 3 ⁇ M test compound was poured on the surface of the sensor chip for 120 seconds, and then the running buffer was poured.
  • MEK1 Recombinant Humanprotein, Inactive (Thermo Fisher Scientific) was used.
  • the obtained sensorgram (a graph showing the time course of the amount of MEK1 bound to the immobilized RAF1) was double-referenced with Biacore Insight Software and further, and further, RAF1 using TIBCO Spotfire.
  • the sensorgram was normalized by the amount of immobilization. Normalized sensorgrams are shown in Figures 4-11. On each sensor gram, the experiment ID, the channel number in Biacore, and the compound number are written in order (however, "no compound” indicates that the test compound does not exist).
  • the horizontal axis (X-axis) represents the time (seconds) after the start of addition of the sample solution
  • the vertical axis (Y-axis) represents the normalized MEK1 binding amount.
  • A549 cells were seeded in a 12-well plate so as to have 400,000 cells per well, and in a 5% carbon dioxide incubator at 37 ° C., using Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum (manufactured by Sigma). It was cultured. The next day, the test compound (0.3 ⁇ M ref-5 or 0.05 ⁇ M compound A-1) or DMSO was added to the medium, and after culturing for 30 minutes or 2 hours, the cells were collected with a cell scraper and solubilized. The extracted protein was separated by SDS-PAGE and transferred to a PVDF membrane.
  • the PVDF membrane is coated with Phospho-MEK1 / 2 (Ser217 / 221) antibody, MEK1 / 2 antibody, Phospho-ERK1 / 2 (Thr202 / Tyr204) antibody, or ERK1 / 2 antibody (all manufactured by Cell Signaling Technology). Processed. After washing the primary antibody, it was treated with an HRP-labeled secondary antibody (manufactured by Cell Signaling Technology Co., Ltd.), and after washing, a signal was detected by a chemiluminescence method using Chemi-Lumi One Super (manufactured by Nakarai Co., Ltd.).
  • FIG. 12 is an electrophoretic image showing the results of Western blotting.
  • "p-MEK” and "p-ERK” represent phosphorylated MEK and phosphorylated ERK, respectively.
  • test compounds CRAF (manufactured by Thermo Fisher), MEK1 (manufactured by Thermo Fisher) and ERK2 (manufactured by Carna Biosciences) were mixed in a buffer containing ATP and reacted at 30 ° C. for 60 minutes. Then, FAM-labeled Erktide (manufactured by Molecular Devices) was added and reacted at 30 ° C. for 45 minutes. Further, IMAP (registered trademark) Progressive Binding Reagent (manufactured by Molecular Devices) was added, and the mixture was reacted at room temperature for 15 minutes. After the reaction, the fluorescent polarized light was measured with a fluorescent plate reader, and the 50% inhibition concentration (IC 50 ) was calculated based on the inhibition rate with respect to the control group containing no test compound. The results are shown in Table 3.
  • test compounds BRAF (manufactured by Eurofins Scientific) and MEK1 (manufactured by Thermo Fisher) were mixed in a buffer containing ATP and reacted at 30 ° C. for 90 minutes. Then, LANCE® Eu-Phospho-MEK1 / 2 (Ser217 / 221) antibody (manufactured by PerkinElmer) was added and reacted at room temperature for 60 minutes. After the reaction, the fluorescence resonance energy transfer was measured with a fluorescent plate reader, and the 50% inhibition concentration (IC 50 ) was calculated based on the inhibition rate with respect to the control group containing no test compound. The results are shown in Table 3.
  • test compound was serially diluted with DMSO, then diluted 25-fold with Ca 2+ , Mg 2+ -free phosphate buffered saline, and 5 ⁇ L per well was dispensed into a 96-well plate.
  • the cell suspension of human lung cancer cell lines A549, Calu-6 or NCI-H2122 (all obtained from ATCC) is subjected to the following cell number using the following medium supplemented with 10% fetal bovine serum (manufactured by Sigma). Prepared as. 95 ⁇ L of this cell suspension was dispensed per well into a plate to which the test compound was added, and cultured in a 5% carbon dioxide incubator at 37 ° C.
  • reaction solution 50 ⁇ L was added to acetonitrile (100 ⁇ L) to stop the metabolic reaction.
  • a 1 ⁇ M warfarin aqueous solution 50 ⁇ L was added as an internal standard to each reaction solution in which the metabolic reaction was stopped.
  • the reaction solution is filtered and LC / MS / MS (LC: NEXTERA manufactured by SHIMADZU; MS: 4000 Qtrap manufactured by ABSicex; column: Ascentis Express C18 HPLC column (5 cm ⁇ 2.1 mm, 2.7 ⁇ m); ionization method: electrospray ionization method. ) was used for the analysis.
  • a human lung cancer cell line Calu-6 having a KRAS mutation was subcutaneously injected into a cell suspension on the ventral side of a nude mouse (CANN.Cg-Foxn1nu / CrlCrlj, female, 5 weeks old, Charles River) with a 26G injection needle. It was transplanted into mice by injection. Divided into mice five groups (8 mice per group) by the dose of the test compound at 17 days after implantation tumor volume reached approximately 200 mm 3, was started administration of the test compound. For mice in group 4 (A-1 administration group), 0.0625 mg / kg, 0.25 mg each time using 10% DMSO / 10% Cremophor EL / 15% PEG400 / 15% HPCD as a solvent (vehicle).
  • Tumor volume was measured at 20, 24 and 27 days after transplantation.
  • the tumor volume was calculated according to the following formula after measuring the major axis and the minor axis of the tumor using a caliper.
  • the results are shown in FIG.
  • FIG. 13 is a graph showing changes over time in tumor volume (mean ⁇ standard deviation).
  • the horizontal axis (X-axis) represents the number of days after transplantation, and the vertical axis (Y-axis) represents the tumor volume.
  • Tumor volume (mm 3 ) 1/2 x major axis (mm) x minor axis (mm) x minor axis (mm)
  • the compounds, salts or solvates of the present disclosure, RAF / MEK complex stabilizers, MEK inhibitors, pharmaceutical compositions, and therapeutic or prophylactic agents for cell proliferation diseases are used to treat cell proliferation diseases, especially cancer. Or it can be used for prevention.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Furan Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PCT/JP2021/002088 2020-01-22 2021-01-21 抗腫瘍活性を有するアリールアミド誘導体 Ceased WO2021149776A1 (ja)

Priority Applications (26)

Application Number Priority Date Filing Date Title
MX2022008722A MX2022008722A (es) 2020-01-22 2021-01-21 Derivados de arilamida con actividad antitumoral.
PE2022001439A PE20230239A1 (es) 2020-01-22 2021-01-21 Derivado de arilamida con actividad antitumoral
EP21744061.9A EP4094804B1 (en) 2020-01-22 2021-01-21 ARYLAMIDE DERIVATIVE WITH ANTITUMORAL ACTIVITY
SI202130384T SI4094804T1 (sl) 2020-01-22 2021-01-21 Arilamidni derivat s protitumorsko aktivnostjo
RS20260093A RS67669B1 (sr) 2020-01-22 2021-01-21 Derivat arilamida sa antitumorskim delovanjem
ES21744061T ES3060503T3 (en) 2020-01-22 2021-01-21 2-(4-cyclopropyl-2-fluoroanilino)-3,4-difluoro-5-[[3-fluoro-2-(methylsulfamoylamino)pyridin-4-yl]methyl]benzamide and similar compounds as raf/mek complex-stabilizers or mek-inhibitors for the treatment of cancer
LTEPPCT/JP2021/002088T LT4094804T (lt) 2020-01-22 2021-01-21 Arilamido dariniai, pasižymintys priešnavikiniu aktyvumu
HRP20260094TT HRP20260094T1 (hr) 2020-01-22 2021-01-21 Derivat arilamida s protutumorskom aktivnošću
CN202180008024.XA CN114929669B (zh) 2020-01-22 2021-01-21 具有抗肿瘤活性的芳基酰胺衍生物
EP25226973.3A EP4725941A1 (en) 2020-01-22 2021-01-21 Arylamide derivative having antitumor activity
BR112022009518A BR112022009518A2 (pt) 2020-01-22 2021-01-21 Derivado de arilamida tendo atividade antitumoral
IL294916A IL294916B1 (en) 2020-01-22 2021-01-21 An arylamide derivative with antitumor activity
KR1020227041183A KR102904379B1 (ko) 2020-01-22 2021-01-21 항종양 활성을 갖는 아릴 아마이드 유도체
DK21744061.9T DK4094804T3 (da) 2020-01-22 2021-01-21 Arylamidderivat med antitumoraktivitet
KR1020227002880A KR102473971B1 (ko) 2020-01-22 2021-01-21 항종양 활성을 갖는 아릴 아마이드 유도체
PL21744061.9T PL4094804T3 (pl) 2020-01-22 2021-01-21 Pochodna aryloamidu o działaniu przeciwnowotworowym
AU2021211553A AU2021211553A1 (en) 2020-01-22 2021-01-21 Arylamide derivative having antitumor activity
JP2021536299A JP6971432B1 (ja) 2020-01-22 2021-01-21 抗腫瘍活性を有するアリールアミド誘導体
MA58427A MA58427B1 (fr) 2020-01-22 2021-01-21 Dérivé d'arylamide ayant une activité antitumorale
CR20220390A CR20220390A (es) 2020-01-22 2021-01-21 Derivados de arilamida con actividad antitumoral
CA3168788A CA3168788A1 (en) 2020-01-22 2021-01-21 Arylamide derivative having antitumor activity
FIEP21744061.9T FI4094804T3 (fi) 2020-01-22 2021-01-21 Aryyliamidijohdannainen, jolla on kasvaimia estävä vaikutus
JP2021178868A JP7693513B2 (ja) 2020-01-22 2021-11-01 抗腫瘍活性を有するアリールアミド誘導体
US17/869,226 US11964950B2 (en) 2020-01-22 2022-07-20 Arylamide derivative having antitumor activity
CONC2022/0011429A CO2022011429A2 (es) 2020-01-22 2022-08-12 Derivados de arilamida con actividad antitumoral
US18/608,369 US20240246922A1 (en) 2020-01-22 2024-03-18 Arylamide derivative having antitumor activity

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2020-008757 2020-01-22
JP2020008757 2020-01-22

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US17/869,226 Continuation US11964950B2 (en) 2020-01-22 2022-07-20 Arylamide derivative having antitumor activity

Publications (1)

Publication Number Publication Date
WO2021149776A1 true WO2021149776A1 (ja) 2021-07-29

Family

ID=76992539

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2021/002088 Ceased WO2021149776A1 (ja) 2020-01-22 2021-01-21 抗腫瘍活性を有するアリールアミド誘導体

Country Status (27)

Country Link
US (2) US11964950B2 (https=)
EP (2) EP4725941A1 (https=)
JP (2) JP6971432B1 (https=)
KR (2) KR102904379B1 (https=)
CN (1) CN114929669B (https=)
AR (1) AR121078A1 (https=)
AU (1) AU2021211553A1 (https=)
BR (1) BR112022009518A2 (https=)
CA (1) CA3168788A1 (https=)
CL (1) CL2022001938A1 (https=)
CO (1) CO2022011429A2 (https=)
CR (1) CR20220390A (https=)
DK (1) DK4094804T3 (https=)
ES (1) ES3060503T3 (https=)
FI (1) FI4094804T3 (https=)
HR (1) HRP20260094T1 (https=)
IL (1) IL294916B1 (https=)
LT (1) LT4094804T (https=)
MA (1) MA58427B1 (https=)
MX (1) MX2022008722A (https=)
PE (1) PE20230239A1 (https=)
PL (1) PL4094804T3 (https=)
PT (1) PT4094804T (https=)
RS (1) RS67669B1 (https=)
SI (1) SI4094804T1 (https=)
TW (2) TWI788763B (https=)
WO (1) WO2021149776A1 (https=)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022019329A1 (ja) * 2020-07-22 2022-01-27 中外製薬株式会社 アリールアミド誘導体を含む組成物
WO2022120354A1 (en) 2020-12-02 2022-06-09 Ikena Oncology, Inc. Tead inhibitors and uses thereof
WO2022120353A1 (en) 2020-12-02 2022-06-09 Ikena Oncology, Inc. Tead inhibitors and uses thereof
WO2022159986A1 (en) 2021-01-25 2022-07-28 Ikena Oncology, Inc. Combination of a 3-(imidazol-4-yl)-4-(amino)-benzenesulfonamide tead inhibitor with an egfr inhibitor and/or mek inhibitor for use in the treatment of lung cancer
WO2023003014A1 (ja) * 2021-07-21 2023-01-26 中外製薬株式会社 アリールアミド誘導体の製造方法
WO2023114984A1 (en) 2021-12-17 2023-06-22 Ikena Oncology, Inc. Tead inhibitors and uses thereof
WO2023140329A1 (ja) 2022-01-21 2023-07-27 中外製薬株式会社 がんの治療または予防用医薬
JPWO2023204259A1 (https=) * 2022-04-20 2023-10-26
WO2024002210A1 (zh) * 2022-06-30 2024-01-04 上海喆邺生物科技有限公司 一种芳香酰胺类衍生物及其在抗肿瘤药物中的应用
US20240139192A1 (en) * 2021-06-09 2024-05-02 Hoffmann-La Roche Inc. Methods and compositions comprising a braf inhibitor and a mek inhibitor
WO2025007811A1 (zh) 2023-07-06 2025-01-09 成都华健未来科技有限公司 一类芳香酰胺类衍生物及其用途
US12234245B2 (en) 2018-07-20 2025-02-25 Genentech, Inc. Sulfonimidamide compounds as inhibitors of interleukin-1 activity
WO2025063275A1 (ja) 2023-09-21 2025-03-27 中外製薬株式会社 アリールアミド誘導体の製造方法
US12351566B2 (en) 2020-01-10 2025-07-08 Immuneering Corporation MEK inhibitors and therapeutic uses thereof

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR121078A1 (es) 2020-01-22 2022-04-13 Chugai Pharmaceutical Co Ltd Derivados de arilamida con actividad antitumoral
WO2022018875A1 (ja) * 2020-07-22 2022-01-27 中外製薬株式会社 アリールアミド誘導体を含む細胞増殖性疾患の治療又は予防用医薬組成物
MA71389A (fr) * 2022-07-08 2025-04-30 Nested Therapeutics, Inc. Inhibiteurs de protéine kinase activée par mitogène (mek)
WO2025146040A1 (zh) * 2024-01-01 2025-07-10 华健未来（成都）科技股份有限公司 芳香酰肼类衍生物及其医药用途

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006011466A1 (ja) 2004-07-26 2006-02-02 Chugai Seiyaku Kabushiki Kaisha Mek阻害物質としての５－置換－２－フェニルアミノ－ベンズアミド類
JP2007511614A (ja) * 2003-11-19 2007-05-10 アレイ バイオファーマ、インコーポレイテッド Ｍｅｋの複素環阻害剤及びその使用方法
WO2007091736A1 (ja) 2006-02-09 2007-08-16 Chugai Seiyaku Kabushiki Kaisha 抗腫瘍活性を有する新規クマリン誘導体
JP2012508203A (ja) * 2008-11-10 2012-04-05 バイエル ファーマ アクチエンゲゼルシャフト 置換スルホンアミドフェノキシベンズアミド
JP2016534027A (ja) * 2013-10-25 2016-11-04 シャンハイ ヘンルイ ファーマスーティカル カンパニー リミテッドＳｈａｎｇｈａｉ Ｈｅｎｇｒｕｉ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． ピリジンのケトン誘導体、それらの製造方法、およびそれらの医薬適用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2594720Y2 (ja) 1993-03-22 1999-05-10 株式会社アーテックスズキ 連結式キャビネット
US8084645B2 (en) 2003-09-19 2011-12-27 Chugai Seiyaku Kabushiki Kaisha 4-phenylamino-benzaldoxime derivatives and uses thereof as mitogen-activated protein kinase kinase (MEK) inhibitors
US7732616B2 (en) * 2003-11-19 2010-06-08 Array Biopharma Inc. Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof
SG177981A1 (en) 2005-05-18 2012-02-28 Array Biopharma Inc 4-(phenylamino)-6-oxo-1, 6-dihydropyridazine-3-carboxamide derivatives as mek inhibitors for the treatment of hyperproliferative diseases
CN101432281B (zh) * 2006-04-19 2013-08-28 诺瓦提斯公司 6-0-取代的苯并*唑和苯并噻唑化合物以及抑制csf-1r信号传导的方法
CL2008001373A1 (es) 2007-05-11 2008-11-21 Bayer Schering Pharma Ag Compuestos derivados de fenilamino-benceno sustituidos; metodo de preparacion; composicion farmaceutica; kit farmceuticos; y uso de dichos compuestos en el tratamiento del cancer.
CA2720818A1 (en) * 2008-04-22 2009-10-29 Marion Hitchcock Substituted phenoxybenzamides
EP2604260B1 (en) 2010-08-10 2017-05-10 Shionogi&Co., Ltd. Novel heterocyclic derivatives and pharmaceutical composition containing same
US20130123255A1 (en) 2011-11-10 2013-05-16 Chugai Seiyaku Kabushiki Kaisha Combination of a pi3k inhibitor and a mek inhibitor
JP2016034900A (ja) 2012-11-26 2016-03-17 中外製薬株式会社 ５−置換−２−フェニルアミノ−ベンズアミド類の製造方法
EP2968345B1 (en) 2013-03-13 2017-12-13 The Regents of The University of Michigan Dual mek/pi3k inhibitors and their application in the treatment of cancer diseases
WO2015038417A1 (en) * 2013-09-10 2015-03-19 Asana Biosciences, Llc Compounds for regulating fak and/or src pathways
CN109988105A (zh) 2014-01-27 2019-07-09 天津滨江药物研发有限公司 作为蛋白激酶抑制剂的氮杂环类化合物及其制备方法
CN105384738B (zh) 2014-08-21 2017-08-29 上海科州药物研发有限公司 作为蛋白激酶抑制剂的杂环类化合物及其制备方法和用途
AR121078A1 (es) 2020-01-22 2022-04-13 Chugai Pharmaceutical Co Ltd Derivados de arilamida con actividad antitumoral
CN115803024B (zh) 2020-07-22 2025-01-10 中外制药株式会社 包含芳基酰胺衍生物的组合物

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007511614A (ja) * 2003-11-19 2007-05-10 アレイ バイオファーマ、インコーポレイテッド Ｍｅｋの複素環阻害剤及びその使用方法
WO2006011466A1 (ja) 2004-07-26 2006-02-02 Chugai Seiyaku Kabushiki Kaisha Mek阻害物質としての５－置換－２－フェニルアミノ－ベンズアミド類
WO2007091736A1 (ja) 2006-02-09 2007-08-16 Chugai Seiyaku Kabushiki Kaisha 抗腫瘍活性を有する新規クマリン誘導体
JP2012508203A (ja) * 2008-11-10 2012-04-05 バイエル ファーマ アクチエンゲゼルシャフト 置換スルホンアミドフェノキシベンズアミド
JP2016534027A (ja) * 2013-10-25 2016-11-04 シャンハイ ヘンルイ ファーマスーティカル カンパニー リミテッドＳｈａｎｇｈａｉ Ｈｅｎｇｒｕｉ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． ピリジンのケトン誘導体、それらの製造方法、およびそれらの医薬適用

Non-Patent Citations (21)

* Cited by examiner, † Cited by third party
Title
ACC. CHEM. RES., vol. 41, pages 1461
ACS MEDCHEM. LETT., vol. 5, no. 4, 2014, pages 309 - 314
ALDRICHIMICA ACTA, vol. 38, 2005, pages 71
ANN. ONCOL., vol. 26, no. 5, 2015, pages 894 - 901
BIOORG. MED. CHEM. LETT., vol. 18, no. 24, 2008, pages 6501 - 6504
BIOORG. MED. CHEM. LETT., vol. 21, no. 6, 2011, pages 1795 - 1801
BIOORG. MED. CHEM. LETT., vol. 23, no. 8, 2013, pages 2384 - 2390
CANCER CELL, vol. 25, no. 5, 2014, pages 697 - 710
CANCER RES, vol. 73, no. 13, 2013, pages 4050 - 4060
CHEM. MED. CHEM., vol. 10, no. 12, 2015, pages 2004 - 2013
CHEM. REV., vol. 95, no. 7, 1995, pages 2457
CHEM. SOC. REV., vol. 40, 2011, pages 5048
J. CLIN. ONCOL., vol. 35, no. 15, 2017, pages 2506
JAMA, vol. 317, no. 18, 2017, pages 1844 - 1853
LITO, PIRO ET AL.: "Disruption of CRAF-Mediated MEK Activation Is Required for Effective MEK Inhibition in KRAS Mutant Tumors", CANCER CELL, vol. 25, 12 May 2014 (2014-05-12), pages 697 - 710, XP028653290, DOI: 10.1016/j.ccr.2014.03.011 *
MOLECULES, vol. 22, 2017, pages e1551
N. ENGL. J. MED., vol. 367, 2012, pages 1694 - 1703
NAT. REV. CLIN. ONCOL., vol. 11, 2014, pages 385 - 400
NATURE, vol. 15, 2018, pages 709 - 720
See also references of EP4094804A4
TETRAHEDRON, vol. 48, no. 44, 1992, pages 9577

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12234245B2 (en) 2018-07-20 2025-02-25 Genentech, Inc. Sulfonimidamide compounds as inhibitors of interleukin-1 activity
US12351566B2 (en) 2020-01-10 2025-07-08 Immuneering Corporation MEK inhibitors and therapeutic uses thereof
CN115803024B (zh) * 2020-07-22 2025-01-10 中外制药株式会社 包含芳基酰胺衍生物的组合物
CN115803024A (zh) * 2020-07-22 2023-03-14 中外制药株式会社 包含芳基酰胺衍生物的组合物
WO2022019329A1 (ja) * 2020-07-22 2022-01-27 中外製薬株式会社 アリールアミド誘導体を含む組成物
WO2022120354A1 (en) 2020-12-02 2022-06-09 Ikena Oncology, Inc. Tead inhibitors and uses thereof
WO2022120353A1 (en) 2020-12-02 2022-06-09 Ikena Oncology, Inc. Tead inhibitors and uses thereof
WO2022159986A1 (en) 2021-01-25 2022-07-28 Ikena Oncology, Inc. Combination of a 3-(imidazol-4-yl)-4-(amino)-benzenesulfonamide tead inhibitor with an egfr inhibitor and/or mek inhibitor for use in the treatment of lung cancer
US20240139192A1 (en) * 2021-06-09 2024-05-02 Hoffmann-La Roche Inc. Methods and compositions comprising a braf inhibitor and a mek inhibitor
CN117677607A (zh) * 2021-07-21 2024-03-08 中外制药株式会社 芳基酰胺衍生物的制造方法
WO2023003014A1 (ja) * 2021-07-21 2023-01-26 中外製薬株式会社 アリールアミド誘導体の製造方法
WO2023114984A1 (en) 2021-12-17 2023-06-22 Ikena Oncology, Inc. Tead inhibitors and uses thereof
WO2023140329A1 (ja) 2022-01-21 2023-07-27 中外製薬株式会社 がんの治療または予防用医薬
WO2023204259A1 (ja) 2022-04-20 2023-10-26 中外製薬株式会社 がんの治療又は予防用医薬
JPWO2023204259A1 (https=) * 2022-04-20 2023-10-26
JP7565132B2 (ja) 2022-04-20 2024-10-10 中外製薬株式会社 がんの治療又は予防用医薬
EP4512401A4 (en) * 2022-04-20 2026-01-28 Chugai Pharmaceutical Co Ltd PHARMACEUTICAL PRODUCT FOR THE TREATMENT OR PREVENTION OF CANCER
WO2024002210A1 (zh) * 2022-06-30 2024-01-04 上海喆邺生物科技有限公司 一种芳香酰胺类衍生物及其在抗肿瘤药物中的应用
WO2025007811A1 (zh) 2023-07-06 2025-01-09 成都华健未来科技有限公司 一类芳香酰胺类衍生物及其用途
WO2025063275A1 (ja) 2023-09-21 2025-03-27 中外製薬株式会社 アリールアミド誘導体の製造方法

Also Published As

Publication number Publication date
CN114929669B (zh) 2024-11-29
EP4094804B1 (en) 2025-12-31
JP2022023958A (ja) 2022-02-08
LT4094804T (lt) 2026-02-25
JP6971432B1 (ja) 2021-11-24
RS67669B1 (sr) 2026-02-27
ES3060503T3 (en) 2026-03-26
DK4094804T3 (da) 2026-02-09
KR102904379B1 (ko) 2025-12-26
JPWO2021149776A1 (https=) 2021-07-29
IL294916A (en) 2022-09-01
MX2022008722A (es) 2022-07-21
US20230002333A1 (en) 2023-01-05
KR20220020390A (ko) 2022-02-18
KR102473971B1 (ko) 2022-12-05
SI4094804T1 (sl) 2026-03-31
PE20230239A1 (es) 2023-02-07
CR20220390A (es) 2022-10-07
EP4094804A4 (en) 2023-11-15
TWI788763B (zh) 2023-01-01
MA58427B1 (fr) 2026-01-30
CO2022011429A2 (es) 2022-08-30
CN114929669A (zh) 2022-08-19
US20240246922A1 (en) 2024-07-25
AU2021211553A1 (en) 2022-09-08
JP7693513B2 (ja) 2025-06-17
CL2022001938A1 (es) 2023-04-14
IL294916B1 (en) 2026-04-01
PT4094804T (pt) 2026-02-03
EP4094804A1 (en) 2022-11-30
TW202313562A (zh) 2023-04-01
EP4725941A1 (en) 2026-04-15
FI4094804T3 (fi) 2026-02-10
KR20220163514A (ko) 2022-12-09
AR121078A1 (es) 2022-04-13
HRP20260094T1 (hr) 2026-03-13
CA3168788A1 (en) 2021-07-29
PL4094804T3 (pl) 2026-03-16
TW202140419A (zh) 2021-11-01
US11964950B2 (en) 2024-04-23
BR112022009518A2 (pt) 2022-08-16

Similar Documents

Publication Publication Date Title
JP6971432B1 (ja) 抗腫瘍活性を有するアリールアミド誘導体
JP7022873B1 (ja) アリールアミド誘導体を含む組成物
JP7168734B2 (ja) アリールアミド誘導体を含む細胞増殖性疾患の治療又は予防用医薬組成物
JP7268255B1 (ja) アリールアミド誘導体の製造方法
JP2026074401A (ja) アリールアミド誘導体を含む組成物
EA047579B1 (ru) Производное ариламида, обладающее противоопухолевой активностью
HK40084009A (en) Composition containing arylamide derivative
EA046648B1 (ru) Композиция, содержащая производное ариламида
HK40073328A (en) Arylamide derivative having antitumor activity
HK40073328B (zh) 具有抗肿瘤活性的芳基醯胺衍生物
HK40084009B (zh) 包含芳基酰胺衍生物的组合物

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 2021536299

Country of ref document: JP

Kind code of ref document: A

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21744061

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 20227002880

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 140150140003001415

Country of ref document: IR

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112022009518

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 3168788

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: NC2022/0011429

Country of ref document: CO

ENP Entry into the national phase

Ref document number: 112022009518

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20220516

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2021744061

Country of ref document: EP

Effective date: 20220822

WWP Wipo information: published in national office

Ref document number: NC2022/0011429

Country of ref document: CO

ENP Entry into the national phase

Ref document number: 2021211553

Country of ref document: AU

Date of ref document: 20210121

Kind code of ref document: A

WWG Wipo information: grant in national office

Ref document number: 2021744061

Country of ref document: EP